Blog

BioSpace: Maryland Booms in the BioCapital Hotbed

As the BioCapital Hotbed continues to grow, the state of Maryland is seeing a boom in life sciences employment as multiple companies build out manufacturing facilities in the state.

Last year, Kite Pharma, a subsidiary of Gilead Sciences, broke ground on their Frederick, Maryland facility that will significantly expand the company’s ability to manufacture a variety of CAR-T therapies, including its previously approved Yescarta. When it becomes fully operational, the facility could employ about 900 people.

Earlier this year, Maryland-based RoosterBio also announced its intention to expand its manufacturing facility. The company will add an additional 5,000 square feet to its 15,500 square-foot site to support the manufacturing of human mesenchymal stem/stromal cell banks. The expansion will allow the company to boost its global cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio said earlier this year. These are just two examples of the exciting things going on in Maryland, Martin Rosendale, chief executive officer of the Maryland Technology Council, an organization focused on advancing the life sciences and technology in Maryland, told BioSpace in an interview.

Click here to read the entire article via BioSpace